CClinicalTrials.gg
Status unknownNCT05028088Updated Sep 5, 2021

Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex

A Phase 4 interventional study of sugammadex in Diaphragm Ultrasonography, Liver Dysfunction and Sugammadex, sponsored by Wuhan Union Hospital, China. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Wuhan Union Hospital, China · Phase 4, Interventional, and Other

The sponsor has not verified this record recently (last verified Aug 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
99
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The use of muscle relaxants is an indispensable in the general anesthesia but is prone to accidents, which are often related to residual muscle relaxant. Therefore, how to timely and effectively eliminate the residual effect of muscle relaxants after surgery has become an urgent clinical problem. Rocuronium is a non-depolarizing muscle relaxant that is primarily metabolized by the liver. Patients with liver dysfunction can affect the metabolic process of rocuronium, thereby delaying the recovery of muscle relaxation. Sugammadex (SUG) is a novel specific antagonist of aminosteroid muscle relaxants, which can effectively antagonize muscle relaxants at different depths. However, whether liver dysfunction affects the antagonistic effect of SUG against rocuronium has not been reported yet. Therefore, the investigators hypothesize that with the increase of patients' liver Child-Pugh grade, the recovery time of rocuronium antagonized by the same dose of SUG after surgery will be prolonged, and the incidence of muscle relaxation residual will be increased in the short term.

Read the detailed description

Main instruments: Drager Fabius anesthesia machine, interlive vue MX600 monitor, Train-Of-Four-Watch muscle relaxation monitor, Philips IU22 Color Doppler Ultrasound Diagnostic Instrument.

Diaphragm ultrasound scan: Prior to anesthesia induction, patients will lie on the bed in a semi-recumbent (45°) position. One operator skilled in ultrasonography will identify and locate diaphragm using the hyperechoic pleural and peritoneal layers with an Philips IU22 Color Doppler Ultrasound Diagnostic Instrument.

Anesthesia method: After the patient entered the operating room, venous access will be opened in the forearm, and routine monitoring of non-invasive BP, ECG, oxygen saturation(SpO₂) and bispectral index(BIS) will be performed. During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. By the time T1=0, endotracheal intubation will be given, and the respiratory parameters will need to be adjusted to volume control ventilation (VT 8-10 ml/kg, respiratory rate(RR) 12-18 times/min, and PETCO2 35-45 mmHg). During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol target-controlled infusion(TCI) will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2.

Muscle relaxation monitoring: TOF-Watch SX muscle relaxation monitor is going to be adopted in our study. The investigators will standardize the electrode position of the muscle relaxation monitor. The distal electrode will be placed at the intersection of the radial edge of the ulnar flexor carpi and the proximal edge of the wrist curve, while the proximal electrode will be placed 3-6 cm away from the distal electrode. Two electrodes will put on either side of the predicted location of the ulnar nerve, which will be able to minimize the impact caused by misjudgment of the location of the nerve.

Measurement of diaphragmatic thickness: When B-mode ultrasound will be used to measure the thickness of the diaphragm, a 5-12MHz linear array ultrasound probe will be put in the left midaxillary line between the 8-10 costale, where is called the diaphragmatic zone of apposition (ZAP). In the breathing exercise, the diaphragm is relatively fixed at ZAP, and the breathing action has little influence on the movement of the diaphragm at ZAP, the diaphragm only shows systolic and diastolic changes. Therefore, the measurement of the diaphragm thickness at ZAP can truly reflect the overall thickness change of the diaphragm during the respiratory cycle. Each value will be measured three times in three consecutive breathing cycles, and the average of the nine measurements will be taken. The values of diaphragmatic thickness at the end of inspirations (DTEI) and diaphragmatic thickness at the end of expirations (DTEE) will be recorded respectively, then the change rate of diaphragmatic thickness fraction (DTF) = (DTEI - DTEE) / DTEE × 100% will be calculated. In addition, the recover rate of DTF = (pre-anesthetic DTEI - postoperative DTEI) / pre-anesthetic DTEI × 100% also will be figured out. Ultrasound measurements should be performed by two physicians with ultrasound experience. Results will be kept confidential to the investigator, who will analyze the ultrasound data when the research is over.

The infusion of anesthetic drugs should be stopped at the end of surgery, and the patients will be transferred into the Post-Anesthesia Care Unit (PACU) with endotracheal catheters and continued monitoring. When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg), respectively. The researchers will record the recovery conditions of diaphragmatic function monitored by bedside ultrasound at the immediate time,10min, 30min and 2h after extubation.

02

Conditions studied

  • Diaphragm Ultrasonography
  • Liver Dysfunction
  • Sugammadex
  • Rocuronium

Browse trials for

03

In context

Liver Diseases

2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.

This study's planned enrollment of 99 is above the median of 50 across 1,323 interventional studies indexed under Liver Diseases.

Browse Liver Diseases studies →

Lead sponsor

Wuhan Union Hospital, China is the lead sponsor of 230 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 1.Age between 18 and 65 years old.
  • 2.Patients scheduled for laparoscopic radical resection of liver cancer under general anesthesia.
  • 3.Patients ASA classification Ⅰ-Ⅲ.
  • 4.Body mass index 18.5 kg/m2 \~ 24.9 kg/m2
  • 5.Able to give informed consent.
  • 6.The surgical position is suitable for BIS monitoring and muscle relaxation monitoring.

Exclusion criteria

Exclusion Criteria:

  • 1.Patients with allergic to rocuronium and SUG.
  • 2.Patients with central and peripheral nervous system diseases, such as polio, Parkinson's disease, peripheral neuropathy, etc..
  • 3.Patients with neuromuscular system diseases, such as multiple sclerosis, myasthenia gravis, atrophic myotonia, etc..
  • 4.Patients with diaphragm dysfunction, pneumothorax, pleural effusion, mediastinal pneumatosis.
  • 5.Pregnant women or nursing mothers.
  • 6.Judging by the researchers, patients with other conditions who are unsuitable for clinical trials.
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    Child-Pugh A

    1. Diaphragm ultrasound scan before induction of anesthesia. 2. Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2. 3. When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg). 4. Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation.

    Drug: sugammadex

  • Experimental
    Child-Pugh B

    1. Diaphragm ultrasound scan before induction of anesthesia. 2. Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2. 3. When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg). 4. Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation.

    Drug: sugammadex

  • Experimental
    Child-Pugh C

    1. Diaphragm ultrasound scan before induction of anesthesia. 2. Anesthesia method: During anesthesia induction, propofol 2.5mg/kg and sufentanil 5μg/kg will be injected intravenously. When the BIS value drops below 60, the muscle relaxation monitor will be calibrated. After T1 and TOF are stable, rocuronium will be injected intravenously at 0.6 mg/kg. During the maintenance stage of anesthesia, the pneumoperitoneum pressure will be at a low level of 8-10mmHg, propofol TCI will be applied to maintain the plasma concentration of 2.5-5.5 μg/mL, remifentanil TCI will be used to keep the plasma concentration of 0.5-5 ng/mL, and rocuronium will be continuously pumped intravenously with 0.3-0.6 mg/kg/h for deep muscle relaxations, with the the post-tetanic twitch count (PTC) value of 1 to 2. 3. When the TOF value was ≥2%, patients in each group will be given SUG (2mg/kg). 4. Diaphragm ultrasound scan at the immediate time,10min, 30min and 2h after extubation.

    Drug: sugammadex

Interventions

  • Drugsugammadex

    This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.

    Also known as: diaphragm ultrasonography

06

What researchers measure

Primary outcomes

  1. the recovery rate of muscle relaxation

    the incidence of residual muscle relaxation at different time points after the operation and the baseline recovery rate of the diaphragm(immediately after extubation, 10minutes, 30minutes and 2hours) When the patients' consciousness and spontaneous breathing are restored, participants can open their eyes according to the doctor's instructions, shake hands firmly, and at the same time, participants can complete the movement of raising their head continuously for more than 5 seconds to remove the tracheal tube.

    Time frame: 2 hours

Secondary outcomes

  1. muscle relaxation onset time

    the period from administration of rocuronium to tracheal intubation

    Time frame: within 3 minutes

  2. intraoperative rocuronium dosage

    The sum of the dose of rocuronium bromide used in induction and maintenance of anesthesia.

    Time frame: through anesthesia completion, up to 2 hours

  3. PACU monitoring time

    Total time patients are monitored in PACU after surgery.

    Time frame: about 2 hours

  4. the incidence of postoperative pulmonary complications

    incidence of postoperative pulmonary complications within seven days

    Time frame: within 7 days after surgery

07

Study locations

1 of 1 sites recruiting
  • Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
08

References and documents

Publications

  • Whittaker R, Wedell D. Review of neuromuscular blockers. Compendium. 1991 Jun;12(6):408, 410, 412 passim. PubMed 1718602 ↗
  • Naguib M, Magboul MM. Adverse effects of neuromuscular blockers and their antagonists. Drug Saf. 1998 Feb;18(2):99-116. doi: 10.2165/00002018-199818020-00002. PubMed 9512917 ↗
  • Arino-Irujo JJ, Calbet-Manueco A, De la Calle-Elguezabal PA, Velasco-Barrio JM, Lopez-Timoneda F, Ortiz-Gomez JR, Fabregat-Lopez J, Palacio-Abizanda FJ, Fornet-Ruiz I, Perez-Cajaraville J. [Neuromuscular blockade monitoring. Part 1]. Rev Esp Anestesiol Reanim. 2010 Mar;57(3):153-60. doi: 10.1016/s0034-9356(10)70190-0. Spanish. PubMed 20422848 ↗
  • Fuchs-Buder T, Schmartz D. [Residual neuromuscular blockade]. Anaesthesist. 2017 Jun;66(6):465-476. doi: 10.1007/s00101-017-0325-1. Erratum In: Anaesthesist. 2017 Aug;66(8):578. doi: 10.1007/s00101-017-0345-x. German. PubMed 28573344 ↗
  • Brull SJ, Kopman AF. Current Status of Neuromuscular Reversal and Monitoring: Challenges and Opportunities. Anesthesiology. 2017 Jan;126(1):173-190. doi: 10.1097/ALN.0000000000001409. PubMed 27820709 ↗
  • Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010 Jul;111(1):120-8. doi: 10.1213/ANE.0b013e3181da832d. Epub 2010 May 4. PubMed 20442260 ↗
  • Aytac I, Postaci A, Aytac B, Sacan O, Alay GH, Celik B, Kahveci K, Dikmen B. Survey of postoperative residual curarization, acute respiratory events and approach of anesthesiologists. Braz J Anesthesiol. 2016 Jan-Feb;66(1):55-62. doi: 10.1016/j.bjane.2012.06.011. Epub 2014 Apr 4. PubMed 26768931 ↗
  • Shay D, Wongtangman K, Eikermann M, Schaefer MS. The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery. Neuropharmacology. 2020 Aug 15;173:108134. doi: 10.1016/j.neuropharm.2020.108134. Epub 2020 May 19. PubMed 32416089 ↗
  • Hawkins J, Khanna S, Argalious M. Sugammadex for Reversal of Neuromuscular Blockade: Uses and Limitations. Curr Pharm Des. 2019;25(19):2140-2148. doi: 10.2174/1381612825666190704101145. PubMed 31272347 ↗
  • Tao J, Zhang W, Yue H, Zhu G, Wu W, Gong W, Fang H, He G, Hu X, Zhao H, Liu A. Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018. Sci Rep. 2019 Sep 26;9(1):13948. doi: 10.1038/s41598-019-50173-5. PubMed 31558731 ↗
  • Sun S, Sun Y, Chen R, Yao C, Xia H, Chen X, Lin Y, Yao S. Diaphragm ultrasound to evaluate the antagonistic effect of sugammadex on rocuronium after liver surgery in patients with different liver Child-Pugh grades: study protocol for a prospective, double-blind, non-randomised controlled trial. BMJ Open. 2022 Feb 1;12(2):e052279. doi: 10.1136/bmjopen-2021-052279. PubMed 35105573 ↗

Individual participant data

Plan to share: No — The investigators don not plan to make the IPD collected in this study available to other researchers.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05028088
Lead sponsor
Wuhan Union Hospital, China
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Jul 1, 2021
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Sep 5, 2021

Study contacts

Yun Lin, MD, PhD.
Contact
franklinyun@hust.edu.cn
+86 02785351606
Shujun Sun
Contact
sunshunjun@foxmail.com
15804066597
Yun Lin, MD, PhD.
principal investigator · Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion